Genenta Science SpA ADR (GNTA NASDAQ) stock market data APIs
$1.8676
0.03(1.6%)
as of December 4, 2025
Try our APIs with
free plan!
Genenta Science SpA ADR Financial Data Overview
Price chart is built with
Anychart
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Prev. Close
1.8676
Open
1.8983
High
1.9246
Low
1.8346
52 wk Range
1.35-6.2
Market Cap
43 584 K
Shares Outstanding
23 432 K
EPS
-0.2
Beta
0.566
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Genenta Science SpA ADR data using free add-ons & libraries
Get Genenta Science SpA ADR Fundamental Data
Genenta Science SpA ADR Fundamental data includes:
- Net Revenue:
- EBITDA: -8 592 703
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-10
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Genenta Science SpA ADR News
New
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeu...
Earnings Momentum Lifts PACS And Nutex; Zynex And Genenta Also Advance After Hours
(RTTNews) - Several stocks posted notable moves in Wednesday's after-hours session, extending momentum from the regular trading day or reversing earlier trends. Earnings announcements and recent finan...
GNTA, BBIO, AMRN Jump After Hours: Key Biotech Catalysts Driving Stock Gains
(RTTNews) - Several biotech and healthcare stocks posted notable gains in after-hours trading, driven by clinical updates, strategic deals, and regulatory milestones. Below is a quick rundown of the t...
Biggest stock movers Monday: RNA, HIVE, and more
[Active trader analyzes market trends using smartphone in a dark setting] FabrikaCr/iStock via Getty Images Stock futures edged higher in Monday's premarket session as optimism over a potential US-Ch...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
